γ‐Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro‐apoptotic and chemosensitizing agent
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND PURPOSE: Activation of signal transducer and activator of transcription 3 (STAT3) play a critical role in the survival, proliferation, angiogenesis and chemoresistance of tumour cells. Thus, agents that suppress STAT3 phosphorylation have potential as cancer therapies. In the present study, we investigated whether the apoptotic, antiproliferative and chemosensitizing effects of γ‐tocotrienol are associated with its ability to suppress STAT3 activation in hepatocellular carcinoma (HCC). EXPERIMENTAL APPROACH: The effect of γ‐tocotrienol on STAT3 activation, associated protein kinases and phosphatase, STAT3‐regulated gene products, cellular proliferation and apoptosis in HCC cells was investigated. KEY RESULTS: γ‐Tocotrienol inhibited both the constitutive and inducible activation of STAT3 with minimum effect on STAT5. γ‐Tocotrienol also inhibited the activation of Src, JAK1 and JAK2 implicated in STAT3 activation. Pervanadate reversed the γ‐tocotrienol‐induced down‐regulation of STAT3, suggesting the involvement of a protein tyrosine phosphatase. Indeed, we found that γ‐tocotrienol induced the expression of the tyrosine phosphatase SHP‐1 and deletion of the SHP‐1 gene by small interfering RNA abolished the ability of γ‐tocotrienol to inhibit STAT3 activation. γ‐Tocotrienol also down‐regulated the expression of STAT3‐regulated gene products, including cyclin D1, Bcl‐2, Bcl‐xL, survivin, Mcl‐1 and vascular endothelial growth factor. Finally, γ‐tocotrienol inhibited proliferation, induced apoptosis and significantly potentiated the apoptotic effects of chemotherapeutic drugs (paclitaxel and doxorubicin) used for the treatment of HCC. CONCLUSIONS AND IMPLICATIONS: Overall, these results suggest that γ‐tocotrienol is a novel blocker of the STAT3 activation pathway, with a potential role in future therapies for HCC and other cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · cited 2×
“…reported to regulate the expression of gene products involved in cell survival, proliferation, angiogenesis and chemoresistance in various solid tumours, as well as haematological malignancies (Aggarwal et al., 2006; 2009a; Gao and Bromberg, 2006; Costantino and Barlocco, 2008; Yu et al., 2009).”
BackgroundA family of cytokine-inducible inhibitors of signalling
Starr, R., Willson, T. A., Viney, E. M., Murray, L. J. L., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A., et al. (1997) · Nature · doi:10.1038/43206 · Cited by 2,066
A new protein containing an SH2 domain that inhibits JAK kinases
Endo, T. A., Masuhara, M., Yokouchi, M., Suzuki, R., Sakamoto, H., Mitsui, K., Matsumoto, A., Tanimura, S., Ohtsubo, M., Misawa, H., et al. (1997) · Nature · doi:10.1038/43213 · Cited by 1,408 · cited 1×
“However, several groups have isolated putative inhibitors for the JAK/STAT pathways by functional or molecular screening of cDNA libraries (Chung et al., 1997; Endo et al., 1997; Starr et al., 1997).”
BackgroundSTATs: Signal Transducers and Activators of Transcription
Ihle, J. N. (1996) · Cell · doi:10.1016/s0092-8674(00)81277-5 · Cited by 1,381
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207 · cited 1×
“…(2011) 163 283–298 293 294 British Journal of Pharmacology (2011) 163 283–298 highly expressed in tumour cells (Epling-Burnette et al., 2001), and Niu et al. (2002) reported that inhibition of STAT3 by a Src inhibitor results in the down-regulation of the expression of the Mcl-1 gene in…”
BackgroundDangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
Grivennikov, S. I., & Karin, M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.005 · Cited by 1,160
Specific Inhibition of Stat3 Signal Transduction by PIAS3
Chung, C. D., Liao, J., Liu, B., Rao, X., Jay, P., Berta, P., & Shuai, K. (1997) · Science · doi:10.1126/science.278.5344.1803 · Cited by 980 · cited 2×
“However, several groups have isolated putative inhibitors for the JAK/STAT pathways by functional or molecular screening of cDNA libraries (Chung et al., 1997; Endo et al., 1997; Starr et al., 1997).”
BackgroundPersistently Activated Stat3 Maintains Constitutive NF-κB Activity in Tumors
Lee, H., Herrmann, A., Deng, J.-H., Kujawski, M., Niu, G., Li, Z., Forman, S., Jove, R., Pardoll, D. M., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.015 · Cited by 683 · cited 1×
“A recent study indicated that STAT3 prolongs NF-kB nuclear retention through acetyltransferase p300-mediated RelA acetylation, thereby interfering with NF-kB nuclear export (Lee et al., 2009).”
BackgroundEpling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9940 · Cited by 633 · cited 2×
“highly expressed in tumour cells (Epling-Burnette et al., 2001), and Niu et al.”
BackgroundGritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1752 · Cited by 563 · cited 1×
“In addition, activation of STAT3 signalling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells (Gritsko et al., 2006).”
BackgroundYamamoto, T., Sekine, Y., Kashima, K., Kubota, A., Sato, N., Aoki, N., & Matsuda, T. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02291-x · Cited by 250 · cited 4×
“Numerous PTP have been implicated in STAT3 signalling, including SHP1, SH-PTP2, TC-PTP, PTEN, PTP-1D, CD45, PTP-epsilon, low molecular weight and PTP (Chiarugi et al., 1998; Kim and Baumann, 1999; Woetmann et al., 1999; Tanuma et al., 2000; Tenev et al., 2000; Gunaje and Bhat, 2001; Irie-Sasaki et al., 2001; Sun and S…”
BackgroundInfluentialActivation of STAT3 by the Hepatitis C Virus Core Protein Leads to Cellular Transformation
Yoshida, T., Hanada, T., Tokuhisa, T., Kosai, K.-I., Sata, M., Kohara, M., & Yoshimura, A. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012127 · Cited by 236 · cited 1×
“Moreover, the role of c-Src kinase has been reported in STAT3 phosphorylation (Yoshida et al., 2002; Grivennikov and Karin, 2010).”
BackgroundKim, H., & Baumann, H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5326 · Cited by 170 · cited 4×
“Numerous PTP have been implicated in STAT3 signalling, including SHP1, SH-PTP2, TC-PTP, PTEN, PTP-1D, CD45, PTP-epsilon, low molecular weight and PTP (Chiarugi et al., 1998; Kim and Baumann, 1999; Woetmann et al., 1999; Tanuma et al., 2000; Tenev et al., 2000; Gunaje and Bhat, 2001; Irie-Sasaki et al., 2001; Sun and S…”
BackgroundInfluentialPin1 is required for the Ser727 phosphorylation-dependent Stat3 activity
Lufei, C., Koh, T. H., Uchida, T., & Cao, X. (2007) · Oncogene · doi:10.1038/sj.onc.1210567 · Cited by 106 · cited 1×
“The STAT3 constitutive plasmid that has been described before (Zhang et al., 2002; Lufei et al., 2007) and was a kind gift from Dr Xinmin Cao at Institute of Moleular and Cell Biology, Singapore.”
MethodPTEN is a negative regulator of STAT3 activation in human papillomavirus-infected cells
Sun, S., & Steinberg, B. M. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-7-1651 · Cited by 101 · cited 4×
“Numerous PTP have been implicated in STAT3 signalling, including SHP1, SH-PTP2, TC-PTP, PTEN, PTP-1D, CD45, PTP-epsilon, low molecular weight and PTP (Chiarugi et al., 1998; Kim and Baumann, 1999; Woetmann et al., 1999; Tanuma et al., 2000; Tenev et al., 2000; Gunaje and Bhat, 2001; Irie-Sasaki et al., 2001; Sun and S…”
BackgroundInfluentialChoudhari, S. R., Khan, M. A., Harris, G., Picker, D., Jacob, G. S., Block, T., & Shailubhai, K. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0561 · Cited by 90 · cited 1×
“Interestingly, STAT3 has also been implicated as a promising target for HCC therapy since inhibition of STAT3 has been reported to induce growth arrest and apoptosis in HCC (Li et al., 2006; 2010a; Choudhari et al., 2007; Kusaba et al., 2007; Tatebe et al., 2008; Lin et al., 2009; Tan et al., 2010).”
Background
Cited by
Antioxidants and human diseases
Rajendran, P., Nandakumar, N., Rengarajan, T., Palaniswami, R., Gnanadhas, E. N., Lakshminarasaiah, U., Gopas, J., & Nishigaki, I. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.06.004 · Cited by 523
Self-citationTherapeutic modulators of STAT signalling for human diseases
Miklossy, G., Hilliard, T. S., & Turkson, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4088 · Cited by 413
Loh, C.-Y., Arya, A., Naema, A. F., Wong, W. F., Sethi, G., & Looi, C. Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00048 · Cited by 348
Self-citationTargeting autophagy using natural compounds for cancer prevention and therapy
Deng, S., Shanmugam, M. K., Kumar, A. P., Yap, C. T., Sethi, G., & Bishayee, A. (2019) · Cancer · doi:10.1002/cncr.31978 · Cited by 320
Self-citationSubramaniam, A., Shanmugam, M. K., Perumal, E., Li, F., Nachiyappan, A., Dai, X., Swamy, S. N., Ahn, K. S., Kumar, A. P., Tan, B. K. H., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.10.002 · Cited by 278
Self-citation
Metadata
- Authors
- Rajendran, P., Li, F., Manu, K. A., Shanmugam, M. K., Loo, S. Y., Kumar, A. P., & Sethi, G.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2011-04-18
- Volume
- 163
- Issue
- 2
- Pages
- 283-298
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1562057738
- Cited by
- 131
- References
- 16
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.